

## Fujifilm Kyowa Kirin Biologics Announces Change of Its Chief Executive Officer

**Tokyo, Japan, October 1, 2017** – Fujifilm Kyowa Kirin Biologics Co., Ltd. (FKB) today announced that its Board of Directors has appointed Yoshifumi Torii, Ph.D. as Chief Executive Officer (CEO).

### 1. The reason for the change

The change is decided to move on the next step of achievement for the launch of FKB327, whose marketing authorization application was accepted for review by the European Medical Agency in March 2017. After establishment of FKB in March 2012, we have been working for development of biosimilar pharmaceuticals.

### 2. New CEO

Effective from October 1

New Position	Name	Previous Position
President and CEO	Yoshifumi Torii	General Manager of Strategic Planning Department

### 3. Retiring CEO

Retired on September 30

Name	Previous Position
Hideaki Nomura	President and CEO

### 4. Curriculum Vitae

President and CEO

Yoshifumi Torii

Date of Birth: January 14, 1967

Citizenship: Japan

Education: Finished Doctoral Course from Graduate School of Pharmaceutical Sciences, The University of Tokyo

Business Experience:

July 2017 – Present	General Manager of Strategic Planning Department, FKB
September 2013	General Manager of European Branch, FKB
October 2008	Manager of Development Division, Kyowa Hakko Kirin Co., Ltd.
April 2003	Manager of Pharmaceutical Development Planning Department, Kirin Brewery Co., Ltd.
April 1994	Joined Kirin Brewery Co., Ltd.